Loading...
•
Jun 30, 2022
Lyell Immunopharma Q2 2022 Earnings Report
Lyell Immunopharma's financial results for Q2 2022 were reported, and business highlights were discussed.
Key Takeaways
Lyell Immunopharma reported revenue of $35.7 million for the second quarter of 2022, primarily related to the GSK Agreement. The company's cash, cash equivalents, and marketable securities totaled $787.0 million as of June 30, 2022, which is expected to fund operations into 2025.
Revenue was $35.7 million for the three months ended June 30, 2022, primarily related to the GSK Agreement.
Net loss for the second quarter ended June 30, 2022 was $36.3 million.
Cash, cash equivalents and marketable securities as of June 30, 2022 were $787.0 million.
The company believes that its cash, cash equivalents and marketable securities balances will be sufficient to meet working capital and capital expenditure needs into 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...